Last update March 9, 2021

Parecoxib Sodium

Compatible

Safe substance and/or breastfeeding is the best option.

Non-steroidal anti-inflammatory drug (NSAID) that functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme. It is a prodrug that is metabolized into valdecoxib, which was withdrawn from the market on 2005 due to cardiovascular toxicity after chronic use.
Prescribed for the limited and short-term treatment of postoperative pain.
Intravenous or intramuscular administration given every 6 to 12 hours and for a maximum of three days.

Its pharmacokinetic data (wide volume of distribution and high percentage of protein binding) explain the observed null or negligible passage to milk, that is not clinically significant (Paech 2012, EMA 2012).
No problems have been reported in infants of mothers given a single dose (Paech 2012).

A limited and short-term treatment administered at a minimum therapeutic dose can be regarded as compatible with breastfeeding.

Alternatives

  • Celecoxib (Safe substance and/or breastfeeding is the best option.)
  • Ibuprofen (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Parecoxib Sodium in other languages or writings:

Group

Parecoxib Sodium belongs to this group or family:

Tradenames

Main tradenames from several countries containing Parecoxib Sodium in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 392 daltons
Protein Binding 98 %
VD 0.79 l/Kg
pKa 4.24 -
Tmax 0.5 - 1 hours
T½ 0.3 (Pare); 8 (Valde) hours
M/P ratio 0.5 -
Theoretical Dose 0.002 mg/Kg/d
Relative Dose 0.47 %

References

  1. Paech MJ, Salman S, Ilett KF, O'Halloran SJ, Muchatuta NA. Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery: a comparison of naive pooled data analysis and nonlinear mixed-effects modeling. Anesth Analg. 2012 Abstract
  2. EMA - Pfizer. Parecoxib Drug Summary 2012 Full text (in our servers)
  3. EMA - Pfizer. Parecoxib. Ficha técnica. 2012 Full text (in our servers)

Total visits

16,059

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM